 The magnetism III trial is a clinical trial that is testing the use of a bispacific antibody or a T-cell engager, namely L-ranatomab, in those patients with relancer refractory multiple maloma. This is a very innovative form of immune therapy where the idea in these bispacific antibodies is to target two antigens. On one hand the antibody will link to the T-cells through an antigen called CD3 and on the other hand it will link into a tumor antigen and in this case it is BCMA, the B-cell maturation antigen and these T-cell engagers are proving to be highly effective because they are leading to very impressive results even in patients who failed actually who received and did not respond or progressed after the other classical treatments like autism inhibitors, imans, but also the monoclonal antibodies, anti-CD38 antibodies. When it comes to the efficacy of a ranatomab the results are quite amazing actually because we're talking about patients who received a median of five prior lines of therapy and despite such an advanced the status and despite the fact that significant proportion of these patients were refractory to the last line of therapy actually you can expect an objective overall response more than 60% including one-third of complete remission. So really this is I think a practice changing breakthrough in the field and obviously now what we are presenting what we presented at this IHA meeting 2023 is the extended follow-up the 15 months follow-up confirming these efficacy results and the median progression free survival and is not yet reached which further highlight the crucial role of the bispecific antibodies especially a ranatomab in the field of freelance refractory multiple maloma. Of course the efficacy of bispecific antibodies like a ranatomab is great but we need to be aware about the side effect and these side effects can be divided into three groups. Two groups are well known well established the CRS a cytokine release syndrome and the neurotoxicity and the third part the third the group of side effects are about the opportunistic infections. When it comes to CRS and neurotoxicity actually the severe CRS or neurotoxicity is extremely low in this manyotism street trial and probably it has to do with the dosage but also to the ramp up I would say way of administration and it is definitely manageable and I don't think it is a matter of concern. When it comes to infectious complications we do have complications related to COVID-19 infection and hopefully this will progressively decrease but we do have also some opportunistic infections and here I would like to emphasize the importance of prevention and prophylaxis measures but also the close monitoring of the patient because if you monitor closely the patient for viruses like CNV like EBV like adenovirus says if you monitor a patient for aspergillosis for instance for toxoplasmosis then you will be able to intervene very early and avoid serious complications also using prophylaxis like antibiotics antiviral antifungal is going to be extremely useful and last but not least an important piece of information in the data we presented at EHA is about when we switch to the twice monthly scan instead of every week actually it looks like that we are decreasing the incidence of infections so in another word actually probably at some point especially beyond six months and those responding patients you can decrease the frequency of the treatment and this will improve in my opinion the infectious complications but also many centers are in using also supplementation with IV immunoglobulins and this is of course extremely helpful from a patient perspective I think these results that we have shown with a Renata map similar to other by specific antibodies are providing a lot of hope because these agents these by specific antibodies are capable to salvage patient who have no other resources no other possibilities so when you look into the immune therapy landscape of multiple myeloma on one hand you have CAR T cells on the other hand you have by specific antibodies but CAR T cells are not available everywhere are not easily accessible but also you need some bridging on the other hand by specific antibodies are off the shelf relatively easy to use with all the precautions and prevention measures and for me they are really a breakthrough in the management of the patient and actually the next step is when we will start using them earlier in the course of the disease but also not a single agent but also in combination with other agents so it's a true I think practice changing family of new drugs and I believe it's an amazing great news for patients